GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lakefront Biotherapeutics LKFT · USD

US listing · 🇺🇸 United States

Compare

33.52

+0.21%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lakefront Biotherapeutics

Its shares trade under the ticker LKFT. It has been listed since 14 May 2015. In the fiscal year to 31 December 2025, it reported revenue of $1.29bn and net income of $371.5m. At that date it held total assets of $3.94bn and shareholders' equity of $3.75bn.

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
14 May 2015
Head office
SCHALIENHOEVEDREEF 20T, 2800 MECHELEN
Incorporated in
C9
Classification
Pharmaceutical Preparations
Filer status
Large accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • GLPG3667 in phase 2 trials for dermatomyositis and lupus in the US and Europe.
  • GLPG5101 CD19 CAR-T product candidate manufactured at point-of-care in Europe.
  • Collaboration with Gilead Sciences for oncology and immunology development.

Weaknesses

  • GLPG5301 BCMA CAR-T product candidate in phase 1/2 trials for multiple myeloma.
  • Formerly Galapagos NV, rebranded in May 2026 to Lakefront Biotherapeutics NV.
  • Headquartered in Mechelen, Belgium, with operations primarily in the US and Europe.

Opportunities

  • Expansion of GLPG5101 and GLPG5301 into new markets in the US and Europe.
  • Gilead Sciences collaboration could lead to new product approvals in oncology.
  • Point-of-care manufacturing for CAR-T products may reduce treatment costs.

Threats

  • Competition from other biotech firms in the oncology and immunology sectors.
  • Regulatory delays in phase 2 trials for GLPG3667 in dermatomyositis and lupus.
  • Potential market saturation in the CAR-T therapy segment for lymphoma and myeloma.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.